Are you over 18 and want to see adult content?
More Annotations
A complete backup of crazyatlanta.com
Are you over 18 and want to see adult content?
A complete backup of haiyangzxw.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of rockstarmind.com
Are you over 18 and want to see adult content?
A complete backup of lunigianafood.it
Are you over 18 and want to see adult content?
A complete backup of allibutchers.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of gianlucadimarzio.com
Are you over 18 and want to see adult content?
Favourite Annotations
Natación Total - Noticias Nacionales e Internacionales de Natación
Are you over 18 and want to see adult content?
Piano Enthalpy | Piano Notes for Hindi Songs
Are you over 18 and want to see adult content?
Ten Most Used BitTorrent Sites Compared
Are you over 18 and want to see adult content?
Medical Supplies, Home Medical Equipment, Home Health Care
Are you over 18 and want to see adult content?
Citizen Femme - A Luxury Women's Travel Guide
Are you over 18 and want to see adult content?
무적천위의 DIY - Automotive 자동차 자가 정비
Are you over 18 and want to see adult content?
Text
MYELOMA MANAGER
The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers deal with the growing glut of information and constantly increasing complexity of myeloma treatment programs. It runs on the user's computer and stores all personal data on the user's computer. None of the user's data is KEY TRENDS IN MYELOMA CARE FOR 2021 HELP FOR VETERANS WITH CANCER Welcome to Veterans Against Myeloma (VAM), a growing team of veterans battling Multiple Myeloma (MM). Over the years, the IMF has been a resource for veterans seeking information about myeloma. Talking with vets has made us aware that many are in need of resources to better understand their diagnosis, find information about myeloma and support ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
INTERNATIONAL STAGING SYSTEM FOR MULTIPLE MYELOMA In 2005, a new staging system was developed by the IMF's research division, the International Myeloma Working Group (IMWG). Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated using a variety of statistical IMWG UNIFORM RESPONSE CRITERIA 1 BGM Durie et al. International uniform response criteria for multiple myeloma. Leukemia (2006) 1-7. Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467-1473; and Kyle RA, Rajkumar SV. Leukemia 2008;23:3-9. Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is by serum FLC levels: CR in such patients is defined as a normal FLC HOW TO TREAT RELAPSED/REFRACTORY MULTIPLE MYELOMA IN 2020 Melflufen is a highly lipophilic alkylating peptide, belonging to the novel class of Peptidase Enhanced Compounds Intracellular amino-peptidases that are overexpressed in most malignant cells, will rapidly cleavemelflufen releasing the hydrophilic, active alkylatingmetabolite
TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappa COVID-19 VACCINATION AND MYELOMA PATIENTS |INT'L MYE FN The IMF strongly recommends that patients with multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS) receive a COVID-19 vaccination with the Pfizer or MODERNA vaccines, whichever is available. These vaccines offer excellent benefits, and in general, have very limited and brief IMWG CRITERIA FOR THE DIAGNOSIS OF MM International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.MYELOMA MANAGER
The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers deal with the growing glut of information and constantly increasing complexity of myeloma treatment programs. It runs on the user's computer and stores all personal data on the user's computer. None of the user's data is KEY TRENDS IN MYELOMA CARE FOR 2021 HELP FOR VETERANS WITH CANCER Welcome to Veterans Against Myeloma (VAM), a growing team of veterans battling Multiple Myeloma (MM). Over the years, the IMF has been a resource for veterans seeking information about myeloma. Talking with vets has made us aware that many are in need of resources to better understand their diagnosis, find information about myeloma and support ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
INTERNATIONAL STAGING SYSTEM FOR MULTIPLE MYELOMA In 2005, a new staging system was developed by the IMF's research division, the International Myeloma Working Group (IMWG). Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated using a variety of statistical IMWG UNIFORM RESPONSE CRITERIA 1 BGM Durie et al. International uniform response criteria for multiple myeloma. Leukemia (2006) 1-7. Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467-1473; and Kyle RA, Rajkumar SV. Leukemia 2008;23:3-9. Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is by serum FLC levels: CR in such patients is defined as a normal FLC HOW TO TREAT RELAPSED/REFRACTORY MULTIPLE MYELOMA IN 2020 Melflufen is a highly lipophilic alkylating peptide, belonging to the novel class of Peptidase Enhanced Compounds Intracellular amino-peptidases that are overexpressed in most malignant cells, will rapidly cleavemelflufen releasing the hydrophilic, active alkylatingmetabolite
TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappa MULTIPLE MYELOMA PAIN Multiple myeloma pain is an unfortunate and frequent component of having the disease. Prevention and management of pain are essential to patients' quality of life. Be proactive about reporting your discomfort; it can interfere with your sleep, mood, and generalactivity level.
INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. NEWLY DIAGNOSED MYELOMA PATIENT RESOURCES Myeloma can be slow-moving or more aggressive. A skilled myeloma specialist is able to determine the best approach for an individual based on his or her unique situation. The International Myeloma Working Group (IMWG) provides the most effective and up-to-date information regarding diagnosis of the MM patient, whether MGUS, SMM,or active myeloma.
HELP FOR VETERANS WITH CANCER Welcome to Veterans Against Myeloma (VAM), a growing team of veterans battling Multiple Myeloma (MM). Over the years, the IMF has been a resource for veterans seeking information about myeloma. Talking with vets has made us aware that many are in need of resources to better understand their diagnosis, find information about myeloma and supportROAD TO THE CURE
With recent trials, the goal is to achieve cure by decisive intervention early for smoldering or active myeloma. To evaluate success, it is essential to use sensitive, reliable, and practical testing for minimal residual disease (MRD). Learn about the Black Swan Research Initiative® and how the success of this bold new initiative is charting the Road to the Cure. ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
MAINTENANCE THERAPY WITH REVLIMID FOR MULTIPLE MYELOM In patients achieving complete or very good partial responses, Rd continuous had an approximately 30-month-longer median time to next treatment versus Rd18 (69.5 vs 39.9 months). While maintenance or continuous therapy with Revlimid is the current standard of care for patients with standard-risk myeloma, sub-group analyses of high-riskpatients
CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH Dr. Salomon Manier (Centre Hospitalier Regional Universitaire de Lille, Lille, France) explains that this study reports on associations of neurotoxicity (NT) with patient and disease characteristics, patient management, and impact on outcomes.GUYS & GEARS 2021
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF's reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education INTERNATIONAL MYELOMA FOUNDATION The International Myeloma Foundation (IMF) advances science and research to improve the lives of myeloma patients while working toward prevention and a cure. TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappa COVID-19 VACCINATION AND MYELOMA PATIENTS |INT'L MYE FN The IMF strongly recommends that patients with multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS) receive a COVID-19 vaccination with the Pfizer or MODERNA vaccines, whichever is available. These vaccines offer excellent benefits, and in general, have very limited and brief IMWG CRITERIA FOR THE DIAGNOSIS OF MM International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.MYELOMA MANAGER
The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers deal with the growing glut of information and constantly increasing complexity of myeloma treatment programs. It runs on the user's computer and stores all personal data on the user's computer. None of the user's data is INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. BLOOD PROTEIN TESTING FOR MYELOMA Many tests are used to assess proteins and other substances in the blood of multiple myeloma patients. These tests measure levels of blood calcium, total protein, serum beta-2 microglobulin, LDH, C-reactive protein, and blood glucose. They are used to monitor the disease and its potential complications. These tests are part of a basic medical exam and are also very useful in HELP FOR VETERANS WITH CANCER Welcome to Veterans Against Myeloma (VAM), a growing team of veterans battling Multiple Myeloma (MM). Over the years, the IMF has been a resource for veterans seeking information about myeloma. Talking with vets has made us aware that many are in need of resources to better understand their diagnosis, find information about myeloma and support IMWG UNIFORM RESPONSE CRITERIA 1 BGM Durie et al. International uniform response criteria for multiple myeloma. Leukemia (2006) 1-7. Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467-1473; and Kyle RA, Rajkumar SV. Leukemia 2008;23:3-9. Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is by serum FLC levels: CR in such patients is defined as a normal FLC ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
INTERNATIONAL MYELOMA FOUNDATION The International Myeloma Foundation (IMF) advances science and research to improve the lives of myeloma patients while working toward prevention and a cure. TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappa COVID-19 VACCINATION AND MYELOMA PATIENTS |INT'L MYE FN The IMF strongly recommends that patients with multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS) receive a COVID-19 vaccination with the Pfizer or MODERNA vaccines, whichever is available. These vaccines offer excellent benefits, and in general, have very limited and brief IMWG CRITERIA FOR THE DIAGNOSIS OF MM International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.MYELOMA MANAGER
The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers deal with the growing glut of information and constantly increasing complexity of myeloma treatment programs. It runs on the user's computer and stores all personal data on the user's computer. None of the user's data is INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. BLOOD PROTEIN TESTING FOR MYELOMA Many tests are used to assess proteins and other substances in the blood of multiple myeloma patients. These tests measure levels of blood calcium, total protein, serum beta-2 microglobulin, LDH, C-reactive protein, and blood glucose. They are used to monitor the disease and its potential complications. These tests are part of a basic medical exam and are also very useful in HELP FOR VETERANS WITH CANCER Welcome to Veterans Against Myeloma (VAM), a growing team of veterans battling Multiple Myeloma (MM). Over the years, the IMF has been a resource for veterans seeking information about myeloma. Talking with vets has made us aware that many are in need of resources to better understand their diagnosis, find information about myeloma and support IMWG UNIFORM RESPONSE CRITERIA 1 BGM Durie et al. International uniform response criteria for multiple myeloma. Leukemia (2006) 1-7. Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467-1473; and Kyle RA, Rajkumar SV. Leukemia 2008;23:3-9. Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is by serum FLC levels: CR in such patients is defined as a normal FLC ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappaPATIENT HANDBOOK
The IMF’s Patient Handbook simplifies the daunting disease. It provides an overview of myeloma, with a focus on getting the correct diagnosis, the tests you really need, initial treatment options, and supportive care and how to get it. MULTIPLE MYELOMA ANEMIA The International Myeloma Foundation medical and editorial content team. Comprised of leading medical researchers, hematologist, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma MULTIPLE MYELOMA TREATMENT OPTIONS In the past decade, many new agents in various drug classes have become available and effective in the treatment of multiple myeloma. Ideally, your frontline therapy (also called induction or first-line therapy) should. effectively control the disease. reverse myeloma-related complications. decrease the risk of early mortality. MYELOMA TODAY: WINTER 2021 The latest edition of Myeloma Today – now available as a free download – features the recent approvals by the FDA of two new myeloma therapies, ABECMA® and PEPAXTO®, as well as COVID-19 pandemic updates and the launch of the IMF’s new M-Power program to help empower individuals and communities to change the course ofmyeloma.
INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. PUBLICATIONS ON MYELOMA MANAGEMENT AND TREATMENT IMWG The information provided in the International Myeloma Working Group’s publications seeks to help guide patients and their doctors to treating myeloma in the most effective way for every individual case. . Blood Cancer J. 2021 Feb 1;11 (2):24. doi: 10.1038/s41408-021-00408-4. SHOULD MYELOMA PATIENTS STOP THEIR CURRENT TREATMENT AND Dr. Brian G.M. Durie discusses if myeloma patients should change their treatment to a new CAR T-cell therapy even if their current treatmentis effective.
LIGHTHOUSE STUDY
Dr. Maria-Victoria Mateos (Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain) explains that this study (OP-108; NCT04649060) evaluates the efficacy and safety of melflufen plus dex and daratumumab versus daratumumab in patients with RRMM previously treated with an immunomodulatory drug (IMiD)and a proteasome inhibitor (PI), a similar indication for UPDATED PHASE 1 RESULTS OF TECLISTAMAB, A BCMA × CD3 What is the background of this study? BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory MM. Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that redirects CD3+ T cells to BCMA-expressing multiple myeloma cells. Inthis video:
TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappa IMWG CRITERIA FOR THE DIAGNOSIS OF MM International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.MYELOMA MANAGER
The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers deal with the growing glut of information and constantly increasing complexity of myeloma treatment programs. It runs on the user's computer and stores all personal data on the user's computer. None of the user's data is COVID-19 VACCINATION AND MYELOMA PATIENTS |INT'L MYE FN The IMF strongly recommends that patients with multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS) receive a COVID-19 vaccination with the Pfizer or MODERNA vaccines, whichever is available. These vaccines offer excellent benefits, and in general, have very limited and brief INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. KEY TRENDS IN MYELOMA CARE FOR 2021 HELP FOR VETERANS WITH CANCER Veterans Against Myeloma. Over the years, the IMF has been committed to providing help for veterans with multiple myeloma cancer. Talking with those who served has made us aware that many need resources to better understand their diagnosis, find information about myeloma and support one another through mutual experiences In response to this INTERNATIONAL STAGING SYSTEM FOR MULTIPLE MYELOMA In 2005, a new staging system was developed by the IMF's research division, the International Myeloma Working Group (IMWG). Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated using a variety of statistical ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
IMWG UNIFORM RESPONSE CRITERIA 1 BGM Durie et al. International uniform response criteria for multiple myeloma. Leukemia (2006) 1-7. Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467-1473; and Kyle RA, Rajkumar SV. Leukemia 2008;23:3-9. Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is by serum FLC levels: CR in such patients is defined as a normal FLC TYPES OF MULTIPLE MYELOMA Multiple myeloma has different types and subtypes. These types are based on the immunoglobulin (protein) produced by the myeloma cell. The various immunoglobulins have different functions in the body. Each immunoglobulin is made up of two heavy chains and two light chains. The five types of heavy protein chains are G, A, D, E, and M. The two types of light protein chains are kappa IMWG CRITERIA FOR THE DIAGNOSIS OF MM International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. The updated criteria for the diagnosis of myeloma represent a paradigm shift in the approach to myeloma and have considerable impact on the management of the disease.MYELOMA MANAGER
The Myeloma Manager™ was developed by the International Myeloma Foundation (IMF) to help patients and caregivers deal with the growing glut of information and constantly increasing complexity of myeloma treatment programs. It runs on the user's computer and stores all personal data on the user's computer. None of the user's data is COVID-19 VACCINATION AND MYELOMA PATIENTS |INT'L MYE FN The IMF strongly recommends that patients with multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS) receive a COVID-19 vaccination with the Pfizer or MODERNA vaccines, whichever is available. These vaccines offer excellent benefits, and in general, have very limited and brief INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. KEY TRENDS IN MYELOMA CARE FOR 2021 HELP FOR VETERANS WITH CANCER Veterans Against Myeloma. Over the years, the IMF has been committed to providing help for veterans with multiple myeloma cancer. Talking with those who served has made us aware that many need resources to better understand their diagnosis, find information about myeloma and support one another through mutual experiences In response to this INTERNATIONAL STAGING SYSTEM FOR MULTIPLE MYELOMA In 2005, a new staging system was developed by the IMF's research division, the International Myeloma Working Group (IMWG). Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated using a variety of statistical ASIAN MYELOMA NETWORK Asian Myeloma Network (AMN) History. On March 17, 2011, the International Myeloma Foundation (IMF) established the Asian Myeloma Network (AMN) at a meeting in Singapore. Comprised of myeloma experts from China, Hong Kong, Malaysia,Taiwan, Japan, South Korea, Singapore, and Thailand, the IMF Asian Myeloma Network — the first of its kindin the
IMWG UNIFORM RESPONSE CRITERIA 1 BGM Durie et al. International uniform response criteria for multiple myeloma. Leukemia (2006) 1-7. Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467-1473; and Kyle RA, Rajkumar SV. Leukemia 2008;23:3-9. Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the only measurable disease is by serum FLC levels: CR in such patients is defined as a normal FLC INTERNATIONAL MYELOMA WORKING GROUP The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a need to conduct collaborative research and produce consensus guidelines for the myeloma community.The first consensus guideline was published in 2003 and the first Annual Brainstorming Summit was organized in Barcelona in 2010. MYELOMA TODAY: WINTER 2021 The latest edition of Myeloma Today – now available as a free download – features the recent approvals by the FDA of two new myeloma therapies, ABECMA® and PEPAXTO®, as well as COVID-19 pandemic updates and the launch of the IMF’s new M-Power program to help empower individuals and communities to change the course ofmyeloma.
BONE MARROW TESTS FOR MULTIPLE MYELOMA Bone marrow tests. Myeloma usually grows inside the bone marrow. Bone marrow tests (aspirate and biopsy) are performed routinely to diagnose multiple myeloma and are also used for monitoring during the course of treatment. A bone marrow biopsy provides: information about the amount of disease. its aggressiveness. MAINTENANCE THERAPY WITH REVLIMID FOR MULTIPLE MYELOM In patients achieving complete or very good partial responses, Rd continuous had an approximately 30-month-longer median time to next treatment versus Rd18 (69.5 vs 39.9 months). While maintenance or continuous therapy with Revlimid is the current standard of care for patients with standard-risk myeloma, sub-group analyses of high-riskpatients
UPDATED PHASE 1 RESULTS OF TECLISTAMAB, A BCMA × CD3 What is the background of this study? BCMA-targeted immunotherapies offer considerable promise for relapsed/refractory MM. Teclistamab (JNJ-64007957) is a BCMA × CD3 bispecific IgG4 antibody that redirects CD3+ T cells to BCMA-expressing multiple myeloma cells. Inthis video:
UPDATED RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY OF Dr. Jesus Berdeja (Sarah Cannon Center for Blood Cancers, Nashville, TN, USA) explains that this study presents updated results of patients treated at the recommended phase II dose in the first-in-human phase I study of teclistamab. Eligible patients had multiple myeloma and were relapsed, refractory or intolerant to established therapies. PHASE 1 STUDY OF CART-DDBCMA, A CAR-T THERAPY UTILIZING A Dr. Matthew J. Frigault (Massachusetts General Hospital, Boston, MA, USA) explains the methods and objective of this study. SUBCUTANEOUS DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE Dr. Efstathios Kastritis (National and Kapodistrian University of Athens, Athens, Greece) discusses the updated results from the phase 3ANDROMEDA study.
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS Dr. Roman Hajek (University Hospital Ostrava, Ostrava, Czech Republic) discusses the IKEMA subgroup analysis. IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED Dr. Larry D. Anderson Jr. (UT Southwestern Medical Center, Dallas, TX, USA) presents the updated data from the KarMMa trial Skip to main contentSHARE ON
____
____
____
____
____
__
DONATION
Choose an optionOne-TimeMonthlyTributeMAKE A DONATION
* Choose an option
* One-Time
* Monthly
* Tribute
SECONDARY NAVIGATION* About Us
* News & Events
* IMF Videos
* Blogs
* Fundraise
Search
Donate Now
MAIN NAVIGATION
* What Is Multiple Myeloma? What is multiple myeloma?Start Here
* Newly Diagnosed
* Do You Have Myeloma? * MGUS, Smoldering Myeloma, and Myeloma* Types of Myeloma
* Urgent Problems at Diagnosis* FAQ
* Tests and Staging
* What Tests Do You Need? * Tests to assess blood cells * Tests to assess kidney function * Tests to assess proteins and other substances in the blood * Tests to assess monoclonal protein* Bone marrow tests
* Imaging studies
* Phases of the Disease * What is Durie/Salmon Staging? * International Staging System (ISS) and Revised ISS (R-ISS)* Treatment
* What Are First-Line Treatments? * Role of Transplant * Role of Consolidation * Role of Maintenance/Continuous Therapy* What Is Relapse?
* Treatment for Early Relapse * Treatment for Subsequent Relapse * FDA-Approved Drugs for Myeloma * Cytoxan (cyclophosphamide) * Darzalex (daratumumab)* Dexamethasone
* Doxil (doxorubicin) * Empliciti (elotuzumab) * Farydak (panobinostat) * Kyprolis (carfilzomib) * Melphalan (Alkeran) * Ninlaro (ixazomib) * Pomalyst (pomalidomide) * Revlimid (lenalidomide) * Thalomid (thalidomide) * Velcade (bortezomib) * Side Effects Management* Anemia
* Bone Disease
* Distress, Fatigue, and Sexuality * Gastrointestinal Problems * Heart and Lung Complications* Kidney Failure
* Myelosuppression
* Pain Management
* Palliative Care
* Peripheral Neuropathy * Steroid Side Effects* Immune Therapy
* Clinical Trials
* A Clinical Trials Glossary * Implications of Participating in a Clinical Trial * Clinical Trials Fact Sheets * Myeloma Matrix 2.0 * Long-Term Care Planning * Mobility and safety * Routine health maintenance * Publications and Videos Learn more about multiple myelomaVisit Our Library
* IMF Publications
* Patient Handbook
* Concise Review
* Understanding Series* Myeloma Minute
* Myeloma Today
* Tip Cards
* Foreign Language Resources* IMF Broadcasts
* Ask Dr. Durie
* Black Swan Research Initiative * IMWG Conference Series * Living Well With Myeloma * Myeloma Information * Nurse Leadership Board Series* Patient Stories
* Patient and Family Seminars * Healthcare Professional Resources* IMWG Publications
* Nurse Leadership Board Summaries * ASH Abstract Summaries * ASCO Abstract Summaries* CME & Education
* Doctors' Edition: Everything You Need to Know About Continuous Treatment in Multiple Myeloma * Master Class: Proteasome Inhibitor-Based Therapy * Doctors' Edition: Proteasome Inhibitors * Getting Clear Answers to Complex Treatment Challenges in MultipleMyeloma
* Resources and Support No matter the situation, we are here for youHow can we help
* IMF Support Network * Find a Support Group * Contact the InfoLine* Being a Caregiver
* Patient and Family Seminars * Regional Community Workshops* Weekly Newsletter
* Smart Patients - Community* Patient Blogs
* 2019 - Orlando, FL * 2018 - San Diego, CA * 2017 - Atlanta, GA * 2016 - San Diego, CA * 2015 - Orlando, FL * 2014 - San Francisco, CA* Diversity
* Overcoming Disparities * IMF African-American Initiative * Myeloma in African Americans* Empower Yourself
* External Resources * Drug Reimbursement Information and Assistance * Government Assistance * Guidance and Support * Housing and Travel Assistance * International Support* Legal Assistance
* Pain Management
* Transplant Resources * Other Cancer Resources* Our Research
The fight against myeloma starts here The Road to the Cure * IMF Medical Research * Black Swan Research Initiative * Black Swan Research Projects * Black Swan Publications * Black Swan Research Initiative Team * Contact the Black Swan Research Initiative * International Myeloma Working Group * IMWG Annual Summit * International Myeloma Working Group (IMWG) Publications * International Myeloma Working Group (IMWG) Conference Series * Asian Myeloma Network * Multiple Myeloma in Asia * Myeloma Clinical Trials in Asia* Road to the Cure
* Nurse Leadership Board * Nurse Leadership Board Members * Nurse Leadership Board Publications* Nursing Webinars
* Nursing Resources
* IMF Research Awards * Brian D. Novis Research Grants * Kyle Lifetime Achievement Award * Brian G.M. Durie Outstanding Achievement Award* Ways to Help
Your donation brings us closer to a cureWhat your gift does
* Ways to Donate
* One-Time
* Monthly
* Planned/Major Giving * Stock/IRA Donation * Tributes and Memorials * Partners in Progress * Other Ways to Give * Member Fundraisers* IMF Shopping Mall
* Shop Amazon
* Buy Myeloma Merchandise* Vehicle Donation
* Attend the Comedy Celebration* Be An Advocate
* Advocacy News
* Advocacy Resources * Veterans Against Myeloma * Global Myeloma Action Network * Global Myeloma Action Network (GMAN) Annual Summit* Susie Durie Grant
* Multiple Myeloma: International Bill of Rights * EU Drug Approval and Reimbursement Policy * Myeloma Action Month* About Us
* News & Events
* IMF Videos
* Blogs
* Fundraise
* Donate Now
Donate
Myeloma Minute
Improving Lives
We provide compassionate and proactive outreach. Our patient education, support, and advocacy programs improve the lives of those impacted by myeloma.Blogs
Finding the Cure
We push for constant scientific advancements around the world. Our groundbreaking research initiatives are on the cusp of finding a cure for multiple myeloma.Our Research
We push for constant scientific advancements around the world. Our groundbreaking research initiatives are on the cusp of finding a cure for multiple myeloma. Improving Lives and Finding the Cure IMPROVING LIVES AND FINDING THE CURE We push for constant scientific advancements around the world. Our groundbreaking research initiatives are on the cusp of finding a cure for multiple myeloma.Blogs
Our Research
a
WE'RE HERE FOR YOU!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.I am a...
- Any -
patient
caregiver
healthcare professionalresearcher
COVID-19 Update
COVID-19 Vaccination and Myeloma Patients Read this page for the IMF’s latest recommendations on receiving the COVID-19 vaccine if you have multiple myeloma (MM), smoldering multiple myeloma (SMM), or monoclonal gammopathy of undetermined significance (MGUS). Click Here to Learn More "Living Well with Myeloma" Webinar on Nutrition Featured speakers are Charise Gleason, MSN, NP-BC, AOCNP®, a nurse practitioner in the Multiple Myeloma program at the Winship Cancer Institute of Emory University in Atlanta; and Stephanie Boyea, MS, RD, LD, an experienced oncology clinical dietitian at the Winship Cancer Institute of Emory University in Atlanta. Virtual ASCO 2021 Includes Important New Data What’s new in myeloma research? IMF Chairman Dr. Brian G.M. Durie shares a preview of some of the most important new findings to be presented at the American Society of Clinical Oncology annual meeting, which kicks off Friday, June 4. FDA Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment of Relapsed/Refractory Multiple Myeloma According to this May 26, 2021 press release from Legend Biotech Corporation, "The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) submitted by Janssen Biotech, Inc. (Janssen) for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy. The Prescription Drug User Fee Act (PDUFA) target action date has been set for November 29, 2021." Click here to read the full press release. Patient & Family Webinar: The Future Is Looking Bright for MyelomaPatients!
Watch a replay of this IMF Patient & Family Webinar. It features late-breaking news about CAR T-cell and other promising therapies: Who are the likely candidates for these treatments and how can eligible patients access them? Dr. Durie shares important updates on COVID-19 vaccines and variants. For newly diagnosed patients, “Myeloma 101” offers a simple introduction to what can be a complex disease, while a myeloma patient shares personal insights. Our expert panel answers questions on what to do when myeloma comes back, how to stay safe during a COVID-19 summer, and more. Week in Review by Dr. Brian Durie Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow DR. BRIAN DURIE’S WEEK IN REVIEW blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line. Read Dr. Brian Durie's Blogsb
Image Left
Floating Circles
COVID-19 and Myeloma COVID-19 and Myeloma: Click here for updates from Dr. Brian G.M. Durie As the COVID-19 respiratory virus spreads around the world, please know that the IMF is here for you. Click here for more resources. This page provides updated guidance to keep you safe. Featured are Dr. Durie’s blogs and FAQs, aimed specifically at myeloma patients, and links to the best sources of COVID-19 news.read more
30 Years of Scientific Achievement Last year marks the International Myeloma Foundation's (IMF) 30th anniversary, celebrating 30 years of scientific achievement with myeloma patient care at the heart of it all. What started in a garage with a borrowed typewriter is now the largest organization focused specifically on multiple myeloma. The IMF continues to push the needle forward toward a cure for myeloma with cure-focused trials and over 40 active research projects around the world. As IMF President and Founder Susie Durie says, "We are this close to the cure. I can see iton the horizon."
WATCH THE VIDEO
a
Image Left
White
Knowledge Is Power: Publications Explore the IMF's library of publications and other resources.Learn More
imf-burgundy
Let Your Voice Be Heard Through Advocacy Advocate for critical health issues that affect the myeloma community.Learn More
ocean
Organize a Fundraiser Apply your skills by creating or joining a fundraising campaignLearn More
blackberry
For the Latest Information, Stay in Touch! Subscribe to the Myeloma Minute for late-breaking news and events. Leave this field blankUpdate My Info
Week in Review
Ocean
First Results from Black Swan-Supported Iceland Study Published Being A New Patient In The Time Of COVID-19 What the New CDC Guidelines Mean for You Staying Healthy in a Time of COVID-19 Patience and Progress in the Search for a CureSee All
#AskDrDurie
Burgundy
What is the best diet for myeloma patients to build a strong immunesystem?
COVID-19 FAQ #33: Which COVID-19 vaccine should myeloma patients get? COVID-19 FAQ #32: How common are COVID-19 infections in myelomapatients?
Are steroids always used as part of myeloma treatment? How does the M-spike correlate to the amount of myeloma protein in thebody?
See All
Start a Movement
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fightagainst myeloma.
Learn About Fundraisersd
Image Left
White
GIVE WHERE MOST NEEDED$25
$50
$100
$150
$250
Other
Learn More
*
*
*
*
*
*
FOOTER
* What is Multiple Myeloma? * Are You Newly Diagnosed? * Essential Tests for Diagnosis and Monitoring * Staging and Risk Stratification* Treatment
* Managing Complications and Side Effects* Clinical Trials
* Long Term Care Planning* FAQ
* Resources and Support * Find a Support Group * Contact the InfoLine* Being a Caregiver
* Publications and Videos * Other Online Resources* Diversity
* Smart Patients - Community* Our Research
* Black Swan Research Initiative * International Myeloma Working Group * Asian Myeloma Network * Nurse Leadership Board * Brian. D Novis Research Grants * Kyle Lifetime Achievement Award * Brian G.M. Durie Outstanding Achievement Award* Take Action
* Donate
* Member FUNdraiser
* Partners in Progress * Advocate in the U.S. * Global Myeloma Action Network (GMAN) * Myeloma Action Month * Buy Myeloma Merchandise* About Us
* Our Mission
* The People of IMF
* Our Partners
* Media Kit
* Financial Reports
* News and Events
* Dr. Durie Blogs
* Upcoming Events
* Making Miracles Newsletter INTERNATIONAL MYELOMA FOUNDATION HEADQUARTERS 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607, USATel: 1-818-487-7455
Contact Us
501(c)(3) not-for-profit charityTax ID: 95-4296919
1990 ‐ 2020 International Myeloma Foundation. All RightsReserved.
SUBFOOTER MENU
* Privacy Policy
* Linking Policy and Terms of Use * Donor Privacy Policy * Accessibility Statement* Sponsors
INFOLINE
We're here to help. Give us a call. U.S. & Canada: 800-452 CURE (2873) Worldwide: 1-818-487-7455_ _
We use cookies on our website to support technical features that enhance your user experience. We also use analytics & advertising services. To opt-out click formore information.
I've read it More informationDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0